Skip to main content
. 2019 Feb;39(1):9–17. doi: 10.14639/0392-100X-1905

Table V.

Comparison of outcomes in HPV-related and unrelated OPSCC patients.

Group CRa LRRa DRa DFSa DSDa
Y/N Y/N Y/N Median (IQR) Y/N
1992-2010 40/9 19/21 5/35 34 (12-65) 25/24
HPV + 14/1 2/12 0/14 65.5 (60-90) 2/13
HPV - 26/8 17/9 5/21 24 (8-60) 23/11
p Ns 0.003 Ns 0.001 0.001
OR (95% CI) 4.3 (0.4-101) 0.08 (0.01-0.5) 0 (0-2.1) 0.07 (0.009-0.4)
2010-2015 54/17 9/45 2/52 17 (8-36) 17/53
HPV + 30/2 2/28 2/28 21.5 (12-38) 3/29
HPV - 24/15 7/17 0/24 15 (7-27) 14/24
p 0.002 0.06 Ns Ns 0.01
OR (95% CI) 9.3 (1.7-66) 0.17 (0.2-1.08) 0.17 (0.03-0.7)
Total 94/26 28/66 7/96 22 (10-42.5) 42/77
HPV + 44/3 4/40 2/41 30.5 (13-54) 5/42
HPV - 50/23 24/26 5/45 16 (8-42) 37/35
p 0.001 < 0.001 Ns 0.018 < 0.001
OR (95% CI) 6.7 (1.7-30.4) 0,1 (0.02-0.3) 0.4 (0.05-2.7) 0.11 (0.03-0.3)

CR: complete response; LRR: loco-regional recurrence; DR: distant recurrence; DFS: disease-free survival; DSD: disease-specific death; Y: yes; N: no; IQR: interquartile range; Ns: not significant; OR: odds ratio; CI: confidence interval

a: data available only for subsets of cases.